Raptor Pharmaceutical Corp. (NASDAQ:RPTP) has licensed for Rett syndrome

Northern, WI 05/21/2013 (usastockreport) – The share prices of an early stage development company in the pharma insutry, Raptor Pharmaceutical Corp. (NASDAQ:RPTP) had surged by 11.66 percent to close at $6.51 for the end of trading session. The share price for the intraday trading of the company ranged between $5.81 and $6.59 per share. The pharmaceutical company witnessed more than average trading volume of 1.51 million shares during the last trading session.

Acquisition of intellectual property license

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) had recently licensed its intellectual property rights for Rett syndrome from the French association named Technology Transfer Accelerator of South Eastern France. This organization represents various French medical research institutes such as Institut Curie, INSERM and Aix-Marseille Université. With the approval of intellectual property license, Raptor Pharmaceutical Corp. (NASDAQ:RPTP) now gets Exclusive Worldwide Rights to the Use of Cysteamine and Related Compounds in the Treatment of MECP2-Associated Conditions.

The Rett syndrome for which the license for treatment had been obtained by Raptor Pharmaceutical Corp. (NASDAQ:RPTP) is diagnosed as a neuro developmental which exclusively affects the females. The syndrome is generally characterized by symptoms such as developmental slowing, slowed brain and head growth, loss of purposeful hand use, problems with walking, seizures and intellectual disability. The Rett syndrome also results in severe disability of performing motor functions which is called as apraxia.

Since the approval of license for Rett Syndrome, the share prices of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) had been gradually increasing to reach new high levels for the past 52 weeks.

Like it? Share it!

Leave A Response